Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2009

View Archived Issues

Ingested hrIFN-alpha preserves beta-cell function in diabetic children

Positive results for peginterferon alfa-2b or alfa-2a in combination with ribavirin in treating HCV

Conjugates of HMG-CoA reductase and renin inhibitors in development at LEK

Postlicense safety data on Gardasil largely consistent with prelicense study data

Merck KGaA claims novel serine/threonine-protein kinase inhibitors

NasalFent filed in U.S. for breakthrough cancer pain

FDA sets date for review of pixantrone NDA

Recent study indicates that AL-1 may be a possible therapy for influenza

Biotec Pharmacon completes patient inclusion in phase III study for oral mucositis

AstraZeneca discloses novel PI3Kbeta inhibitor for use in antithrombotic therapy

Schering-Plough launches Remeron for depression in Japan

Novel dihydrofolate reductase inhibitors described by Universidad de Murcia

New sensitive cardiac troponin assays may improve diagnosis of MI and ACS

EpiCept claims caspase activators and apoptosis inducers as oncolytics

Rohto discovers alpha-MSH inhibitors for the treatment of dermatological disorders

Ipsen and Debiopharm enter worldwide license agreement for Debio-0931

PAION completes patient recruitment for phase IIa study of CNS-7056

U.K. launch for Regurin XL for overactive bladder

Sinovac Biotech's H1N1 vaccine approved in China

Sucampo withdraws European MAA for lubiprostone for idiopathic constipation

Biogen Idec announces proposal to acquire Facet Biotech

FDA approves Zevalin expanded label in follicular non-Hodgkin's lymphoma

Independent research confirms superiority of midkine combined with conventional cancer markers

Neublastin enters into phase I clinical development for neuropathic pain

Glenmark Pharmaceuticals describes vanilloid receptor 1 modulators for the treatment of pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...